Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
3. Abbott wins Xience Prime nod in Japan
Abbott (NYSE:ABT) won approval from the Japanese Ministry of Health, Labor & Welfare for its next-generation Xience Prime coronary stent.
2. Sapien heart valve gets FDA date for Edwards Lifesciences
The FDA’s circulatory devices panel will review Edwards Lifesciences pre-market approval application for a high-risk indication for its Sapien replacement heart valve.
1. Medtronic confirms Hauser’s findings
Medtronic (NYSE:MDT) fired back against accusations that it’s running a whisper campaign against arch-rival St. Jude Medical (NYSE:STJ), saying its own review of an FDA database supports the controversial findings of a study tying St. Jude’s recalled Riata defibrillator leads with deaths from internal short circuits.
